Corvus Pharmaceuticals, Inc. (CRVS)

Key Insights

• Soquelitinib demonstrated strong efficacy in Phase 1 atopic dermatitis trials with 75% of patients achieving EASI 75 at the highest dose (200mg twice daily) in the longest cohort, significantly outperforming placebo and showing dose-dependent response improvements.
• Notably, soquelitinib achieved durable remissions without disease rebound or rescue medication requirements during post-treatment follow-up periods (30-90 days), contrasting favorably with published data from approved systemic therapies that typically show rebound within four weeks.
• Safety profile was excellent with equal adverse event rates between treatment (41.7%) and placebo (41.7%), all Grade 1-2, no serious adverse events, and no dose modifications required, supporting potential for favorable regulatory pathway.
• Efficacy was maintained in treatment-resistant patients who had previously failed systemic therapies (35% of cohort), demonstrating potential competitive advantage in a patient population with high unmet medical need and limited options.